Lumos Earns $507K BARDA Payout as FebriDx Waiver Opens Door to 300,000+ US Sites
Lumos Diagnostics secures US$507,377 BARDA milestone payment following FebriDx CLIA waiver clearance
Lumos Diagnostics has received a US$507,377 milestone payment from the Biomedical Advanced Research and Development Authority (BARDA) following achievement of US FDA CLIA waiver clearance for its FebriDx rapid diagnostic test. The payment brings total funding received under the CLIA waiver study to US$2,984,571, providing non-dilutive capital to support ongoing clinical programmes whilst validating regulatory progress with a US government agency.
The milestone payment was issued under contract number 75A50124C00051 with BARDA, the division of the US Department of Health and Human Services responsible for advancing medical countermeasures and preparedness solutions. This funding mechanism allows the company to extend its clinical development capacity without issuing equity, preserving shareholder value whilst advancing key programmes including the paediatric expansion of FebriDx.
When big ASX news breaks, our subscribers know first
What is a CLIA waiver and why does it matter for diagnostics companies?
A CLIA waiver is a US FDA designation that allows diagnostic tests to be performed in simple healthcare settings without laboratory infrastructure or specialised personnel. Under the Clinical Laboratory Improvement Amendments (CLIA) framework, diagnostic tests are classified by complexity: waived, moderate, or high. Only tests granted waived status can be deployed outside traditional laboratory environments.
Prior to this clearance, FebriDx held moderate-complexity classification, restricting its use to laboratory settings where trained personnel and quality control systems are mandated. The CLIA waiver removes these requirements, enabling deployment in primary care offices, urgent care clinics, retail pharmacies, and community health centres where laboratory infrastructure does not exist. This regulatory shift transforms FebriDx from a laboratory-restricted product to one deployable across the broadest range of US healthcare settings.
For diagnostics companies, CLIA waiver clearance represents a critical commercial inflection point. The designation dramatically expands the addressable market whilst reducing barriers to adoption, as healthcare providers no longer require specialised training or laboratory certification to deploy the test.
FebriDx now accessible to over 300,000 US healthcare locations
The CLIA waiver expands FebriDx applicability to over 300,000 US locations holding a Certificate of Waiver, according to the Centers for Medicare & Medicaid Services CLIA database. The test delivers results in 10 minutes and differentiates between bacterial and non-bacterial respiratory infections, supporting clinical decision-making on antibiotic prescribing without requiring complex laboratory infrastructure or specialised training.
FebriDx can now be deployed across:
- Primary care physician offices
- Urgent care clinics
- Retail health and pharmacy clinics
- Community health centres
The addressable distribution footprint has expanded dramatically with a single regulatory clearance, enabling point-of-care deployment in settings that serve the majority of patients presenting with acute respiratory infections.
Market opportunity expands to US$1 billion-plus
The CLIA waiver unlocks access to approximately 80 million US patients annually presenting with acute respiratory infections at primary and urgent care centres, representing a US$1.0 billion-plus market opportunity. This addressable market is approximately 15 times larger than the market available under the previous moderate-complexity classification, according to Precision Business Insights data.
| Metric | Value |
|---|---|
| Addressable patient population | 80 million per annum |
| Market opportunity | US$1.0+ billion |
| Expansion multiple vs prior classification | 15x |
The commercial opportunity has fundamentally changed from a niche laboratory market to a mass-market point-of-care proposition. The test’s ability to differentiate bacterial from non-bacterial infections in 10 minutes addresses a clinical need across primary care settings where rapid decision-making on antibiotic therapy is required.
BARDA partnership extends capacity for paediatric programme
The BARDA funding provides both capital and technical expertise as the company advances its diagnostic solutions towards broader clinical deployment. CEO and Managing Director Doug Ward highlighted the dual benefit of the partnership:
Doug Ward, CEO and Managing Director
“BARDA’s assistance provides not only meaningful non-dilutive funding that extends our capacity to run critical studies, including our paediatric program, but also brings technical expertise as we advance our diagnostic solutions toward broader clinical use.”
The funding extends the company’s capacity to conduct critical studies, with the paediatric programme representing a potential further expansion of the addressable patient population. Paediatric clearance would enable FebriDx deployment in settings treating children with respiratory infections, a demographic segment where rapid differentiation of bacterial versus viral infections carries particular clinical significance given prescribing considerations in younger patients.
The BARDA relationship provides both funding and credibility. BARDA’s remit includes advancing medical countermeasures for public health threats, positioning the partnership as validation of FebriDx’s potential role in infectious disease management and antimicrobial stewardship programmes.
The next major ASX story will hit our subscribers first
Pathway to commercial deployment
The CLIA waiver clearance represents a significant commercial milestone, positioning FebriDx to reach tens of millions more patients without infrastructure barriers. The test supports more informed clinical decision-making and potentially reduces unnecessary antibiotic prescribing, addressing both clinical and public health objectives around antimicrobial stewardship.
FebriDx is now cleared for broad US deployment across primary care, urgent care, retail pharmacy, and community health settings where the majority of acute respiratory infection presentations occur. The company has removed the regulatory bottleneck that previously restricted distribution to laboratory environments. The execution challenge shifts to commercial distribution and market penetration across the newly accessible 300,000-plus locations now able to deploy the test under the Certificate of Waiver framework.
The combination of CLIA waiver clearance and ongoing BARDA support positions the company to advance commercialisation whilst maintaining clinical development momentum across paediatric and other expansion programmes without dilutive capital requirements.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they hit the ASX.